Book contents
- Antitrust Policy in Health Care Markets
- Antitrust Policy in Health Care Markets
- Copyright page
- Dedication
- Contents
- Figures
- Tables
- Acknowledgments
- Table of Cases
- 1 Health Care Markets and Competition Policy
- 2 Antitrust Policy in the United States
- Part I Monopoly
- Part II Seller Cartels
- Part III Monopsony
- Part IV Buyer Cartels
- Part V Mergers and Acquisitions
- Index
- References
Part II - Seller Cartels
Published online by Cambridge University Press: 24 November 2022
Book contents
- Antitrust Policy in Health Care Markets
- Antitrust Policy in Health Care Markets
- Copyright page
- Dedication
- Contents
- Figures
- Tables
- Acknowledgments
- Table of Cases
- 1 Health Care Markets and Competition Policy
- 2 Antitrust Policy in the United States
- Part I Monopoly
- Part II Seller Cartels
- Part III Monopsony
- Part IV Buyer Cartels
- Part V Mergers and Acquisitions
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Antitrust Policy in Health Care Markets , pp. 113 - 254Publisher: Cambridge University PressPrint publication year: 2022
References
References
Ayres, Ian. (1987). How Cartels Punish: A Structural Theory of Self-Enforcing Collusion. Columbia Law Review 87: 295–325.CrossRefGoogle Scholar
Blair, Roger D., and Durrance., Christine Piette (2014). Restraints on Quality Competition, Journal of Competition Law and Economics 10: 27–46.Google Scholar
Bolado, Carolina. (2020). Fla. Cancer Group Nabs Partial Win in Adventist Antitrust Suit. Law360. www.law360.com/articles/1316731/fla-cancer-group-nabs-partial-win-in-adventist-antitrust-suit.Google Scholar
Federal Trade Commission. (2003). FTC Settles Price-Fixing Charges Brought against Baton Rouge Physician Groups and Their Agent. FTC. www.ftc.gov/news-events/press-releases/2003/07/ftc-settles-price-fixing-charges-brought-against-baton-rouge.Google Scholar
Frank, Richard G., and McGuire, Thomas G.. (2019). Market Concentration and Potential Competition in Medicare Advantage. Commonwealth Fund. www.commonwealthfund.org/sites/default/files/2019-02/Frank_market_concentration_medicare_advantage_ib_0.pdf.Google ScholarPubMed
Reuters. (2016). China Says Fines Medtronic Local Unit $17.2 Million for Price Fixing. Reuters. www.reuters.com/article/us-china-antitrust-medtronic-idUSKBN13W2YN.Google Scholar
Stigler, George. (1964). A Theory of Oligopoly. Journal of Political Economy 72: 44–61.Google Scholar
Stigler, George. (1968). Price and Non-Price Competition. Journal of Political Economy 74: 149–154.CrossRefGoogle Scholar
References
Benner, Katie. (2020). Generic Drug Maker Admits to Fixing Prices for Cholesterol Medication. New York Times. www.nytimes.com/2020/05/07/us/politics/justice-department-antitrust-drugs.html.Google Scholar
Berndt, Ernst R., and Aiken, Murray L.. (2011). Brand Loyalty, Generic Entry and Price Competition in Pharmaceuticals in the Quarter Century after the 1984 Waxman-Hatch Legislation. International Journal of the Economics of Business 18: 177–201.CrossRefGoogle Scholar
Centers for Medicare & Medicaid Services. (2021). NHE Fact Sheet. www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NHE-Fact-Sheet.Google Scholar
Clincalc. (2021). Pravastatin Sodium: Drug Usage Statistics, United States, 2008–2018. ClinCalc. https://clincalc.com/DrugStats/Drugs/PravastatinSodium.Google Scholar
Conrad, Ryan, and Lutter, Randall. (2019). Generic Competition and Drug Prices: New Evidence Linking Greater Generic Competition and Lower Generic Drug Prices. US Food and Drug Administration. www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/generic-competition-and-drug-prices.Google Scholar
Dave, Chintan V., Hartzema, Abraham, and Kesselheim, Aaron S.. (2017). Prices of Generic Drugs Associated with Numbers of Manufacturers. New England Journal of Medicine 377: 2597–2598.CrossRefGoogle ScholarPubMed
Department of Justice. (2019a). Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations. www.justice.gov/opa/pr/pharmaceutical-company-admits-price-fixing-violation-antitrust-law-resolves-related-false.Google Scholar
Department of Justice. (2019b). Second Pharmaceutical Company Admits to Price Fixing, Resolves Related False Claims Act Violations. www.justice.gov/opa/pr/second-pharmaceutical-company-admits-price-fixing-resolves-related-false-claims-act.Google Scholar
Department of Justice. (2020). Generic Drugs – Update 2020. www.justice.gov/atr/division-operations/antitrust-division-update-2020/generic-drugs.Google Scholar
Department of Justice. (2021). Generic Drugs Investigation Targets Anticompetitive Schemes – Division Update Spring 2021. www.justice.gov/atr/division-operations/division-update-spring-2021/generic-drugs-investigation-targets-anticompetitive-schemes.Google Scholar
Frakt, Austin. (2017). When a Drug Coupon Helps You but Hurts Fellow Citizens. New York Times. www.nytimes.com/2017/09/25/upshot/when-a-drug-coupon-helps-you-but-hurts-fellow-citizens.html.Google Scholar
Lande, Robert H. (1993). Are Antitrust “Treble” Damages Really Single Damages? Ohio State Law Journal 54: 115–174.Google Scholar
Mikulic, Matej. (2020). Savings through Generic Drug Usage in the US, 2008–2019. Statista. www.statista.com/statistics/277492/savings-through-generic-drug-usage-us/.Google Scholar
Poitras, Colin. (2019). Price-Fixing, Fraud and Collusion, CT Attorney General Offers Sobering View of Generic Drug Market. Yale School of Medicine. https://medicine.yale.edu/news-article/price-fixing-fraud-and-collusion-ct-attorney-general-offers-sobering-view-of-generic-drug-market/.Google Scholar
References
Areeda, Phillip, and Hovenkamp, Herbert. (2021). Antitrust Law, Vol. XII. 5th ed. New York: Wolters Kluwer.Google Scholar
Areeda, Phillip E., Hovenkamp, Herbert, Blair, Roger D., and Durrance, Christine Piette. (2021). Antitrust Law, Vol. IIA, 5th ed. New York: Wolters Kluwer.Google Scholar
Barker, Holly. (2020). Glumetza Class Certified in Lawsuit Alleging $2.3 Billion Injury. Bloomberg Law. https://news.bloomberglaw.com/mergers-and-antitrust/gulemtza-class-certified-in-lawsuit-alleging-2-3-billion-injury.Google Scholar
Bauman, Valerie. (2020). Pharma Pay-for-Delay Deals Called “Cost of Doing Business.” Bloomberg Law. https://news.bloomberglaw.com/pharma-and-life-sciences/pharma-pay-for-delay-settlements-cost-of-doing-business.Google Scholar
Blair, Roger D., and Cotter, Thomas F.. (2002). Are Settlements of Patent Disputes Illegal Per Se? Antitrust Bulletin 47: 491–539.CrossRefGoogle Scholar
Brittain, Blake. (2021). Lupin Agrees to Pay $150 Mln to settle Glumetza Antitrust Claims. Reuters. www.reuters.com/legal/litigation/lupin-agrees-pay-150-mln-settle-glumetza-antitrust-claims-2021-09-21/.Google Scholar
Federal Trade Commission. (2019). Last Remaining Defendant Settles FTC Suit That Led to Landmark Supreme Court Ruling on Drug Company “Reverse Payments.” www.ftc.gov/news-events/press-releases/2019/02/last-remaining-defendant-settles-ftc-suit-led-landmark-supreme.Google Scholar
Federal Trade Commission. (2020). Agreements Filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003: Overview of Agreements Filed in FY 2017. www.ftc.gov/system/files/documents/reports/agreements-filed-federal-trade-commission-under-medicare-prescription-drug-improvement-modernization/mma_report_fy2017.pdf.Google Scholar
Ford, Mark A., Spaeth, Peter A., and Luo, Christina. (2020). Unprecedented State Law on Pharmaceutical “Reverse Payments” Goes into Effect. www.wilmerhale.com/en/insights/client-alerts/20200108-unprecedented-state-law-on-pharmaceutical-reverse-payments-goes-into-effect.Google Scholar
Gallasch, Sven. (2016). Activating Actavis in Europe: The Proposal of a “Structure Effects-Based” Analysis for Pay-for-Delay Settlements. Legal Studies 36: 683–705.CrossRefGoogle Scholar
Grabowski, Henry, Kyle, Margaret, Mortimer, Richard, Long, Genia, and Kirson, Noam. (2011). Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act. Health Affairs 30: 2157–2166.CrossRefGoogle ScholarPubMed
Grabowski, Henry, and Vernon, John. (1986). Longer Patents for Lower Imitation Barriers: The 1984 Drug Act. American Economic Review 76: 195–198.Google Scholar
Karas, Laura, Anderson, Gerard F., and Feldman, Robin. (2019 ). Pharmaceutical ‘Pay-for-Delay’ Reexamined: A Dwindling Practice or a Persistent Problem? Hastings Law Journal 71: 959–974.Google Scholar
Leonard, Mike. (2021). Jazz Pharma, Hikma, Others Ordered to Face Xyrem Antitrust Case. Bloomberg Law. https://news.bloomberglaw.com/us-law-week/jazz-pharma-hikma-others-ordered-to-face-xyrem-antitrust-case.Google Scholar
Lichtenberg, Nick. (2019). Celgene Settles Class Action Antitrust Case for $55M: Law Firm. Bloomberg Law. https://news.bloomberglaw.com/pharma-and-life-sciences/celgene-settles-class-action-antitrust-case-for-55m-law-firm.Google Scholar
Pierson, Brendan. (2021). Bausch to Pay $300 Mln in Antitrust Suit over Diabetes Drug. Reuters. www.reuters.com/business/healthcare-pharmaceuticals/bausch-pay-300-mln-antitrust-suit-over-diabetes-drug-2021-09-09/.Google Scholar
Sullivan, Thomas. (2019). Allergan Subsidiary Forest Settles for $750 Million in Namenda Class Action Pay for Delay Suit. Policymed. www.policymed.com/2019/11/allergan-subsidiary-forest-settles-for-750-million-in-namenda-class-action-pay-for-delay-suit.html.Google Scholar
Towey, Jamie, and Albert, Brad. (2019). Then, Now, and Down the Road: Trends in Pharmaceutical Patent Aettlements after FTC v. Actavis. www.ftc.gov/news-events/blogs/competition-matters/2019/05/then-now-down-road-trends-pharmaceutical-patent.Google Scholar
US Food and Drug Administration. (2021). Drug Approval Process. www.fda.gov/media/82381/download.Google Scholar
Yasiejko, Christopher. (2020). Pfizer Files More Patent-Infringement Suits on Ibrance Capsules. Bloomberg Law. https://news.bloomberglaw.com/ip-law/pfizer-files-more-patent-infringement-suits-on-ibrance-capsules.Google Scholar
References
Ayres, Ian. (1987). How Cartels Punish: A Structural Theory of Self-Enforcing Collusion. Columbia Law Review 87: 295–325.CrossRefGoogle Scholar
Balto, David. (2017). Federal and State Litigation Regarding Pharmacy Benefit Managers. PBM Watch. www.pbmwatch.com/pbm-litigation-overview.html.Google Scholar
Bergin, Jessica M. (2019). A Primer on Pharmacy Benefit Managers. Antitrust Health Care Chronicle 33: 7–15.Google Scholar
Campbell, Todd. (2020). CVS Announces Plan to Eliminate Co-Pays for Diabetes Drugs. Fool. www.fool.com/investing/2020/01/29/cvs-announces-plan-to-eliminate-diabetes-co-pays.aspx.Google Scholar
Centers for Disease Control and Prevention. (2020). National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf.Google Scholar
Chamberlin, Edward. (1933). The Theory of Monopolistic Competition. Cambridge, MA: Harvard University Press.Google Scholar
Cubanski, Juliette, Neuman, Tricia, True, Sarah, and Damico, Anthony. (2020). Insulin Costs and Coverage in Medicare Part D. Kaiser Family Foundation. www.kff.org/medicare/issue-brief/insulin-costs-and-coverage-in-medicare-part-d/.Google Scholar
Diabetesmuseum München. (2020). Insulin: 2020 – Thanks for 99 Years of Insulin. https://diabetesmuseum.de/insulin.Google Scholar
Envision Intelligence. (2018). Globally, Top 10 Insulin Manufacturers Are Dominated by Europe and North America. www.envisioninteligence.com/blog/globally-top-10-insulin-manufacturers/.Google Scholar
Fortune Business Insights. (2018). Human Insulin Market Size, Share & Industry Analysis, by Type (Analogue Insulin, Traditional Human Insulin), by Diabetes Type (Type 1, Type 2), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, Online Pharmacy), and Regional Forecast, 2019–2026. www.fortunebusinessinsights.com/industry-reports/human-insulin-market-100395.Google Scholar
Hayes, Tara O’Neill, Barnhorst, Margaret, and Farmer, Josee. (2020). Federal and State Actions to Address Insulin Costs. American Action Forum. www.americanactionforum.org/insight/federal-and-state-actions-to-address-insulin-costs/.Google Scholar
Hua, Xinyang, Carvalho, Natalie, Tew, Michelle, Huang, Elbert S., Herman, William H., and Clarke, Philip. (2016). Expenditures and Prices of Antihyperglycemic Medications in the United States: 2002–2013. Journal of the American Medical Association 315: 1400–1402.Google Scholar
Leonard, Mike. (2021). EpiPen Gouging Suit Advances against Mylan, CVS, Express Scripts. Bloomberg Law. https://news.bloomberglaw.com/antitrust/epipen-gouging-suit-advances-against-mylan-cvs-express-scripts.Google Scholar
Mylan N.V. (2020). Mylan and Biocon Announce US FDA Approval of Semglee. Cision PR Newswire. www.prnewswire.com/news-releases/mylan-and-biocon-announce-us-fda-approval-of-semglee-insulin-glargine-injection-301074847.html.Google Scholar
Pepall, Lynne, Richards, Dan, and Norman, George. (2014). Industrial Organization: Contemporary Theory and Empirical Applications. 5th ed. Hoboken, NJ: Wiley.Google Scholar
Rosenfeld, Louis. (2002). Insulin: Discovery and Controversy. Clinical Chemistry 48: 2270–2288.CrossRefGoogle ScholarPubMed
Rowley, William R., Bezold, Clement, Arikan, Yasemin, Byrne, Erin, and Krohe, Shannon. (2017). Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Population Health Management 20: 6–12.CrossRefGoogle ScholarPubMed
Sanofi. (2019). How Much Should I Expect to Pay for Lantus? www.lantus.com/-/media/EMS/Conditions/Diabetes/Brands/lantus-final/Header/Lantus-Pricing.pdf.Google Scholar
Seeley, Elizabeth, and Kesselheim, Aaron S.. (2019). Pharmacy Benefit Managers: Practices, Controversies, and What Lies Ahead. The Commonwealth Fund. www.commonwealthfund.org/publications/issue-briefs/2019/mar/pharmacy-benefit-managers-practices-controversies-what-lies-ahead.Google ScholarPubMed
Stark, S., and Wood, J.. (2020). Humalog Insulin: Investigating the Potential Implications of Insulin Price Hikes on Company Financial Data. https://insulin.substack.com/p/humalog-insulin-investigating-the?s=r.Google Scholar
Stigler, George J. (1964). A Theory of Oligopoly. Journal of Political Economy 72: 44–61.CrossRefGoogle Scholar
Sullivan, Thomas. (2021). Biden Administration Rescinds Trump Administration Insulin Pricing Rule. Policymed. www.policymed.com/2021/10/biden-administration-rescinds-trump-administration-insulin-pricing-rule.html.Google Scholar
Tribble, Sarah Jane. (2015). You Can Buy Insulin without a Prescription, but Should You? KHN. https://khn.org/news/you-can-buy-insulin-without-a-prescription-but-should-you/.Google Scholar
US Health and Human Services. (2019). Trump Administration Proposes to Lower Drug Costs by Targeting Backdoor Rebates and Encouraging Direct Discounts to Patients. www.hhs.gov/sites/default/files/20190131-fact-sheet.pdf.Google Scholar
US Senate Finance Committee. (2021). Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug. www.finance.senate.gov/imo/media/doc/Grassley-Wyden%20Insulin%20Report%20(FINAL%201).pdf.Google Scholar
US White House. (2020). Executive Order on Access to Affordable Life-Saving Medications. www.whitehouse.gov/presidential-actions/executive-order-access-affordable-life-saving-medications/.Google Scholar
Vecchio, Ignazio, Tornali, Cristina, Bragazzi, Nicola Luigi, and Martini, Mariano. (2018). The Discovery of Insulin: An Important Milestone in the History of Medicine. Frontiers in Endocrinology. www.frontiersin.org/articles/10.3389/fendo.2018.00613/full.Google ScholarPubMed
Walker, Joseph. (2021). FDA Lets Pharmacies Substitute Branded Insulin with Knockoff Product, in First for a Biologic Drug. Wall Street Journal. www.wsj.com/articles/fda-lets-pharmacies-substitute-branded-insulin-with-knockoff-product-in-first-for-a-biologic-drug-11627589200.Google Scholar
Wheeler, Lydia. (2020). High Court Upholds State Law Reining in Pharmacy Drug Middlemen. Bloomberg Law. https://news.bloomberglaw.com/us-law-week/high-court-upholds-state-law-reining-in-pharmacy-drug-middlemen.Google Scholar
References
Allensworth, Rebecca Haw. (2017). Foxes at the Henhouse: Occupational Licensing Boards Up Close. California Law Review 105: 1567–1610.Google Scholar
Allensworth, Rebecca Haw. (2020). Licensed to Pill. The New York Review. www.nybooks.com/daily/2020/07/21/licensed-to-pill/.Google Scholar
Areeda, Philip, and Hovenkamp, Herbert. (2021). Antitrust Law. 5th ed., Vol. II. New York: Wolters Kluwer.Google Scholar
Blair, Roger D., and Durrance, Christine Piette. (2015a). Economic Effects of Licensing Health Care Professions. Antitrust Health Care Chronicle 28: 29–34.Google Scholar
Blair, Roger D., and Durrance, Christine Piette. (2015b). Licensing Health Care Professionals, State Action, and Antitrust Policy. University of Iowa Law Review 100: 1943–1967.Google Scholar
Bulusu, Siri. (2021). FTC Settles with Alabama Dental Board over Teledentistry Rules. Bloomberg Law. https://news.bloomberglaw.com/health-law-and-business/ftc-settles-with-alabama-dental-board-over-teledentistry-rules.Google Scholar
Bulusu, Siri, Hao, Claire, and Mulvaney, Erin. (2021). Worker License Rules Emerge as FTC Competition Oversight Priority. Bloomberg Law. https://news.bloomberglaw.com/antitrust/worker-license-rules-emerge-as-ftc-competition-oversight-priority.Google Scholar
Edlin, Aaron S., and Allensworth, Rebecca Haw. (2014). Cartels by Another Name: Should Licensed Occupations Face Antitrust Scrutiny? University of Pennsylvania Law Review 162: 1093–1164.Google Scholar
Federal Trade Commission. (2014a). FTC Letter to Massachusetts House of Representatives. www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-staff-comment-massachusetts-house-representatives-regarding-house-bill-6-h.2009-concerning-supervisory-requirements-nurse-practitioners-nurse-anesthetists/140123massachusettnursesletter.pdf.Google Scholar
Federal Trade Commission. (2014b). Prepared Statement of the Federal Trade Commission: Competition and the Potential Costs and Benefits of Professional Licensure. www.ftc.gov/system/files/documents/public_statements/568171/140716professionallicensurehouse.pdf.Google Scholar
Federal Trade Commission. (2015a). FTC Letter to South Carolina House of Representatives. www.ftc.gov/system/files/documents/advocacy_documents/ftc-staff-comment-south-carolina-representative-jenny.horne-regarding-house-bill-3508-3078-advanced-practice-registered-nurse-regulations/151103scaprn.pdf.Google Scholar
Federal Trade Commission. (2015b). FTC Staff Guidance on Active Supervision of State Regulatory Boards Controlled by Market Participants. www.ftc.gov/system/files/attachments/competition-policy-guidance/active_supervision_of_state_boards.pdf.Google Scholar
Federal Trade Commission. (2020). FTC Letter to Kansas House of Representatives. www.ftc.gov/system/files/documents/advocacy_documents/ftc-staff-comment-kansas-house-representatives-concerning-kansas-house-bill-2412/v200006kansashb2412aprnscomment.pdf.Google Scholar
Friedman, Milton. (1962). Capitalism and Freedom. Chicago: University of Chicago Press.Google Scholar
Grzinic, Barbara. (2022). 9th Circuit Aligns with SmileDirectClub’s Antitrust Claims. Reuters. www.reuters.com/legal/litigation/9th-circuit-aligns-with-smiledirectclubs-antitrust-claims-2022-03-18/.Google Scholar
Hicks, John. (1939). The Foundations of Welfare Economics. Economic Journal 49: 696–712.CrossRefGoogle Scholar
Just, Richard E., Hueth, Darrell L., and Schmitz, Andrew. (2004), The Welfare Economics of Public Policy. Northampton, UK: Edward Elgar.Google Scholar
Kaldor, Nicholas. (1939). Welfare Propositions in Economic and Interpersonal Comparisons of Utility. Economic Journal 49: 549–552.CrossRefGoogle Scholar
Kleiner, Morris M. (2015). Reforming Occupational Licensing Policies. The Hamilton Project. www.brookings.edu/wp-content/uploads/2016/06/thp_kleinerdiscpaper_final.pdf.Google Scholar
National Conference of State Legislatures. (2017). The State of Occupational Licensing: Research, State Policies and Trends. www.ncsl.org/Portals/1/HTML_LargeReports/occupationallicensing_final.htm.Google Scholar
National Conference of State Legislatures. (2020). Occupational Licensing Final Report: Assessing State Policies and Practices. www.ncsl.org/research/labor-and-employment/occupational-licensing-final-report-assessing-state-policies-and-practices637425196.aspx.Google Scholar
Norris, Conor, and Timmons, Edward J.. (2020). Restoring Vision to Consumers and Competition to the Marketplace: Analyzing the Effects of Required Prescription Release. Journal of Regulatory Economics 57: 1–19.CrossRefGoogle Scholar
Obama White House. (2015). Occupational Licensing: A Framework for Policymakers. https://obamawhitehouse.archives.gov/sites/default/files/docs/licensing_report_final_nonembargo.pdf.Google Scholar